Concepedia

Evan Rogers

ER

8

Publications

741

Citations

8

H-Index

2016

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Fate Therapeutics (United States)

Seoul National University Hospital

Massachusetts General Hospital

Evan Rogers is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

2016–2021

8

Publications

8

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho et al. · Cancer Discovery · 2018 · 463 citations · Full text

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations

Brion W. Murray, Dayong Zhai, Wei Deng et al. · Molecular Cancer Therapeutics · 2021 · 84 citations · Full text

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Alexander Drilon, Evan Rogers, Dayong Zhai et al. · Annals of Oncology · 2019 · 55 citations

, , +9

The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.

Alexander Drilon, Dayong Zhai, Evan Rogers et al. · Journal of Clinical Oncology · 2020 · 50 citations

, , +17

TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants

J. Jean Cui, Dayong Zhai, Wei Deng et al. · European Journal of Cancer · 2016 · 29 citations

, , +8

Rows per page

1–5 of 8